Skyrizi Subcutaneous (on-body injector) — Medica

Initial criteria

• Patient is age ≥ 18 years
• According to the prescriber, the patient will receive three induction doses with Skyrizi intravenous within 3 months of initiating therapy with Skyrizi subcutaneous
• Medication is prescribed by or in consultation with a gastroenterologist

Reauthorization criteria

• Patient has been established on the requested drug for at least 6 months
• Patient experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., fecal markers such as fecal calprotectin, serum markers such as C-reactive protein, endoscopic assessment, or reduced corticosteroid dose) OR patient experienced an improvement compared with baseline in at least one symptom (e.g., decreased pain, fatigue, stool frequency, or rectal bleeding)

Approval duration

Initial: 6 months; Reauthorization: 1 year